Read by QxMD icon Read

Angiotensin bevacizumab

Rhian M Touyz, Sandra M S Herrmann, Joerg Herrmann
The vascular endothelial growth factor (VEGF) signaling pathway (VSP) fulfills a cardinal role in endothelial cells and its inhibition has profound cardiovascular impact. This is true not only for the normal vasculature but also for the tumor vasculature when VSP inhibitors are used as anti-angiogenic therapies. Generalized endothelial dysfunction predisposes to vasoconstriction, atherosclerosis, platelet activation, and thrombosis (arterial more than venous). All of these have been reported with VSP inhibitors and collectively give rise to vascular toxicities, the most concerning of which are arterial thromboembolic events (ATE)...
March 21, 2018: Journal of the American Society of Hypertension: JASH
Satoru Nihei, Junya Sato, Toshiyuki Harada, Shoichi Kuyama, Toshiro Suzuki, Nobutsugu Waga, Yoshitaka Saito, Shigeki Kisara, Atsuko Yokota, Kouji Okada, Masami Tsuchiya, Kazufumi Terui, Yumiko Tadokoro, Takeshi Chiba, Kenzo Kudo, Satoshi Oizumi, Akira Inoue, Naoto Morikawa
PURPOSE: The objective of this study was to investigate the effect of renin-angiotensin system inhibitors (RASIs) on bevacizumab (BV)-induced proteinuria in non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: We retrospectively reviewed the medical records of NSCLC patients receiving BV between 2008 and 2014 at 11 hospitals. The patients were categorized into three groups according to their antihypertensive drug use: RASI user, non-RASI user, and non-user groups...
April 12, 2018: Cancer Chemotherapy and Pharmacology
Victor A Levin, James Chan, Meenal Datta, Jennie L Yee, Rakesh K Jain
Given prior studies that suggest the use of angiotensin system inhibitors (ASIs) is associated with prolonged overall survival (OS) in glioblastoma (GBM) patients, we evaluated the effect of ASIs in glioma patients receiving chemotherapy and/or bevacizumab (BEV). Using retrospective IRB-approved electronic chart review of newly diagnosed WHO grade 2-4 glioma patients from the Kaiser Permanente Tumor Registry of Northern California, we evaluated the impact of ASIs on OS by Cox proportional hazard model analysis for subgroups who received cytotoxic therapy, cytotoxic therapy with BEV, or BEV alone, as well as those with recurrent GBM (rGBM)...
September 2017: Journal of Neuro-oncology
Lisa Derosa, Hassane Izzedine, Laurence Albiges, Bernard Escudier
Arterial hypertension (HTN) is a class effect of anti-vascular endothelial growth factor (VEGF) therapies, including the monoclonal antibody bevacizumab. Data are conflicting regarding the role of the renin-angiotensin system on angiogenesis and recent data suggest that the use of angiotensin system inhibitors (ASIs; angiotensin receptor blockers or angiotensin-converting enzyme inhibitors) is associated with improved survival in metastatic renal cell carcinoma (mRCC), particularly when used with VEGF targeted therapies...
October 10, 2016: Oncology Reviews
Alex R Menter, Nikki M Carroll, Lori C Sakoda, Thomas Delate, Mark C Hornbrook, Rakesh K Jain, Lawrence H Kushi, Virginia P Quinn, Debra P Ritzwoller
INTRODUCTION: Preclinical studies suggest that angiotensin system inhibitors (ASI) and bevacizumab improve tumor perfusion and chemotherapy efficacy. We performed a retrospective study to examine whether concomitant ASI use during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) was associated with improved overall survival (OS) in patients with advanced nonsquamous, non-small-cell lung cancer (NS-NSCLC). PATIENTS AND METHODS: In a retrospective cohort study, adult patients diagnosed with stage IIIB or IV NS-NSCLC between 2005 and 2011 were identified from tumor registries at 1 of 4 Kaiser Permanente regions...
March 2017: Clinical Lung Cancer
Hiroki Osumi, Satoshi Matsusaka, Takeru Wakatsuki, Mitsukuni Suenaga, Eiij Shinozaki, Nobuyuki Mizunuma
The local renin-angiotensin system promotes angiogenesis and vascular proliferation via expression of vascular endothelial growth factor or epidermal growth factor receptor. We hypothesized that angiotensin II type-1 receptor blockers (ARBs) in combination with bevacizumab (Bev) may improve clinical outcomes in patients with metastatic colorectal cancer (mCRC). A total of 181 patients with histopathologically confirmed mCRC treated with first-line oxaliplatin-based chemotherapy in combination with Bev were enrolled between June, 2007 and September, 2010...
November 2015: Molecular and Clinical Oncology
Diana Moreno-Muñoz, Juan R de la Haba-Rodríguez, Francisco Conde, Laura M López-Sánchez, Araceli Valverde, Vanessa Hernández, Antonio Martínez, Carlos Villar, Auxiliadora Gómez-España, Ignacio Porras, Antonio Rodríguez-Ariza, Enrique Aranda
BACKGROUND: Currently, there are no predictive biomarkers for anti-angiogenic strategies in cancer, but response to anti-angiogenic drugs is associated with development of hypertension secondary to treatment. Therefore, this study explored the clinical relevance of genetic polymorphisms in some components of the renin-angiotensin system (RAS). MATERIAL AND METHODS: Genomic DNA was isolated from peripheral blood from 95 metastatic breast or colorectal cancer patients treated with bevacizumab, and AGTR1-A1166C (rs5186), AGT-M235T (rs699) SNPs and ACE I/D (rs4646994) polymorphisms were genotyped using RT-PCR...
December 2015: European Journal of Clinical Investigation
J Salvador, L Manso, J de la Haba, A Jaen, E Ciruelos, M C de Villena, M Gil, A Murias, A Galan, C Jara, J Bayo, J M Baena, J Casal, J R Mel, I Blancas, P Sanchez Rvira
BACKGROUND: Efficacy and safety data for combining bevacizumab, gemcitabine, and paclitaxel for locally advanced/metastatic breast cancer are limited. PATIENTS AND METHODS: AVALUZ trial evaluates the combination of bevacizumab 10 mg/kg, gemcitabine 2,000 mg/m(2) plus paclitaxel 150 mg/m(2), on days 1 and 15 of each 28-day course in previously untreated HER-2 negative patients. RESULTS: Median progression-free survival (PES): 12.3 months...
February 2015: Clinical & Translational Oncology
Ahmet Taner Sümbül, Umut Dişel, Nurzen Sezgin, Ahmet Sezer, Fatih Köse, Ali Ayberk Beşen, Zehra Sümbül, Hüseyin Abalı, Özgür Özyılkan
BACKGROUND: Standard treatment of colorectal cancer includes both cytostatic chemotherapy and targeted therapies. Bevacizumab, targeting the VEGF receptor, is one of the primary targeted therapies that achieve better response rate and survival rate as compared to combination chemotherapy. To the best of our knowledge, there is no established single marker that can be used as a predictive marker in bevacizumab therapy. MATERIAL AND METHODS: We enrolled 24 patients with the diagnosis of metastatic colorectal cancer in our study...
2014: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
P Sánchez-Rovira, M A Seguí, A Llombart, E Aranda, A Antón, A Sánchez, M Lomas, A Jaén, M Fernández, I Porras, E Dalmau, S Morales, J de la Haba-Rodríguez
PURPOSE: The primary aim of this trial was to assess the rate of pathologic complete responses (pCR) of doxorubicin/cyclophosphamide (AC) followed by bevacizumab/docetaxel (BT), as neoadjuvant therapy for breast cancer (BC). Furthermore, the association between biomarkers and the pCR was explored. METHODS: Patients with HER-negative operable stage II-III BC ≥ 2 cm were enrolled. Four cycles of AC (A 60 mg/m(2) and C 600 mg/m(2), every 3 weeks) followed by 4 cycles of BT (B 15 mg/kg and T 75 mg/m(2), every 3 weeks), were planned...
October 2013: Clinical & Translational Oncology
Yan Zhang, Yan-rong Jiang, Qiang Lu, Hong Yin, Yong Tao
PURPOSE: Apelin, a novel cytokine, was reported to regulate angiogenesis. The aim of this study was to investigate the correlation between apelin and retinopathy of prematurity (ROP), between apelin and the other known angiogenic cytokines including vascular endothelial growth factor (VEGF) and hypoxia-induced factor-1a (HIF-1a). METHODS: The study included 36 ROP patients who underwent vitrectomy. Previous intravitreal bevacizumab (IVB) was performed in 18 patients (IVB group)...
March 2013: Retina
Javier A Montero, Jose M Ruiz-Moreno, Eugenia Sanchis-Merino, Santiago Perez-Martin
PURPOSE: To evaluate the effect of concomitant systemic therapy in patients with choroidal neovascularization secondary to age-related macular degeneration (AMD) treated by intravitreal bevacizumab and to propose a mechanism for different interindividual response. METHODS: Retrospective, nonrandomized, single-center, consecutive interventional case series study. Forty-six eyes from 46 patients with choroidal neovascularization secondary to age-related macular degeneration were treated by monthly intravitreal 1...
March 2013: Retina
Fei-jiao Ge, Jian-ming Xu
No abstract text is available yet for this article.
July 2010: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
Christos Vaklavas, Daniel Lenihan, Razelle Kurzrock, Apostolia Maria Tsimberidou
BACKGROUND: Therapies targeting vascular endothelial growth factor (VEGF) are associated with hypertension, cardiotoxicity, and thromboembolic events. METHODS: All prospective phase I-III clinical trials published up to December 2008 of approved anti-VEGF therapies (bevacizumab, sunitinib, sorafenib) and relevant literature were reviewed. RESULTS: The rates of Common Toxicity Criteria (version 3) grade 3-4 hypertension with bevacizumab, sunitinib, and sorafenib were 9...
2010: Oncologist
Hassane Izzedine, Christophe Massard, Jean Philippe Spano, François Goldwasser, David Khayat, Jean Charles Soria
Proteinuria is a dose-related side-effect occurring after inhibition of vascular endothelial growth factor (VEGF) signalling and may reflect severe glomerular damage. The inhibition of the VEGF signalling axis induces downexpression or suppression of nephrin, an important protein for the maintenance of the glomerular slit diaphragm, sometimes leading to nephritic syndrome and/or glomerular thrombotic microangiopathy, the main-associated kidney disease. A MEDLINE search was carried out using the following criteria: (1) all MEDLINE listings as of 01-01-2000 with abstracts; (2) English language; and (3) Humans...
January 2010: European Journal of Cancer
Takeo Yasu, Yoshiyuki Miyasaka, Hideo Chubachi, Rai Shimoyama
The patient was a 73-year-old female with sigmoid colon cancer, who underwent resection of sigmoid colon cancer and liver metastasis. She was treated with 5-fluorouracil and levofolinate calcium(sLV5FU2)plus bevacizumab(BV) for advanced colorectal cancer. She was treated with angiotensin II receptor blocker(ARB)because hersystolic blood pressure was 200 mmHg and her diastolic blood pressure 100 mmHg after five courses of BV therapy. As a result, her blood pressure was controlled. It was possible to administer BV...
January 2009: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Guillaume Bollée, Natacha Patey, Géraldine Cazajous, Caroline Robert, Jean-Michel Goujon, Fadi Fakhouri, Patrick Bruneval, Laure-Hélène Noël, Bertrand Knebelmann
BACKGROUND: Drugs targeting the VEGF pathway are associated with renal adverse events, including proteinuria, hypertension and thrombotic microangiopathy (TMA). Most cases of TMA are reported secondary to bevacizumab. It was shown recently that sunitinib, a small molecule inhibiting several tyrosine kinase receptors, including VEGF receptors, can also induce proteinuria, hypertension and biological features of TMA. Case. A 44-year-old woman with a history of malignant skin hidradenoma was started on sunitinib for refractory disease...
February 2009: Nephrology, Dialysis, Transplantation
Amitkumar Pande, Jeffrey Lombardo, Edward Spangenthal, Milind Javle
BACKGROUND: Hypertension (HT) is a common complication of anti-angiogenic therapy. Its incidence, treatment and complications are undefined. PATIENTS AND METHODS: Retrospective review of patients treated with bevacizumab (BV) from 2003-5. Common toxicity criteria (CTC) for adverse events version 3.0 were used. RESULTS: Fifty-five out of the 154 patients treated with BV (35%) experienced HT. Eleven (20%) developed a new onset HT and 44 (80%) experienced an exacerbation of pre-existing HT...
September 2007: Anticancer Research
Daniel Roncone, Anjali Satoskar, Tibor Nadasdy, J Paul Monk, Brad H Rovin
BACKGROUND: A 59-year-old man who had undergone a left nephrectomy for renal cell carcinoma was found to have metastatic disease during a restaging examination. The patient was started on treatment with interferon alpha2b plus bevacizumab, a humanized monoclonal anti-vascular endothelial growth factor antibody. After 9 months of this therapy, the patient developed proteinuria, which gradually increased to over 6 g/day. INVESTIGATIONS: Physical examination, urine and blood analysis, biopsy of the right kidney, and histologic evaluation of the non-neoplastic portion of the left nephrectomy specimen...
May 2007: Nature Clinical Practice. Nephrology
M Bayes, X Rabasseda, J R Prous
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, This issue focuses on the following selection of drugs: A-007, A6, adalimumab, adenosine triphosphate, alefacept, alemtuzumab, AllerVax Ragweed, amphora, anakinra, angiotensin-(1-7), anidulafungin, apomine, aripiprazole, atomoxetine hydrochloride, avanafil; BAL-8557, becatecarin, bevacizumab, biphasic insulin aspart, BMS-188797, bortezomib, bosentan, botulinum toxin type B, brivudine; Calcipotriol/betamethasone dipropionate, caspofungin acetate, catumaxomab, certolizumab pegol, cetuximab, CG-0070, ciclesonide, cinacalcet hydrochloride, clindamycin phosphate/benzoyl peroxide, cryptophycin 52, Cypher; Dabigatran etexilate, darapladib, darbepoetin alfa, decitabine, deferasirox, desloratadine, dexanabinol, dextromethorphan/quinidine sulfate, DMF, drotrecogin alfa (activated), duloxetine hydrochloride; E-7010, edaravone, efalizumab, emtricitabine, entecavir, eplerenone, erlotinib hydrochloride, escitalopram oxalate, estradiol valerate/dienogest, eszopiclone, exenatide, ezetimibe; Fondaparinux sodium, fulvestrant; Gefitinib, gestodene, GYKI-16084; Hyaluronic acid, hydralazine hydrochloride/isosorbide dinitrate; Imatinib mesylate, indiplon, insulin glargine; Juzen-taiho-to; Lamivudine/zidovudine/abacavir sulfate, L-arginine hydrochloride, lasofoxifene tartrate, L-BLP-25, lenalidomide, levocetirizine, levodopa/carbidopa/entacapone, lexatumumab, lidocaine/prilocaine, lubiprostone, lumiracoxib; MAb-14...
September 2006: Methods and Findings in Experimental and Clinical Pharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"